Breast cancer quantitative proteome and proteogenomic landscape

Consortia Oslo Breast Cancer Research Consortium (OSBREAC)

Research output: Contribution to journalArticle

Abstract

In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

Original languageEnglish (US)
Article number1600
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

proteome
Proteome
breast
Tumors
tumors
cancer
Breast Neoplasms
proteins
Proteins
Neoplasms
genes
Therapeutic Human Experimentation
Messenger RNA
Carcinoma, Intraductal, Noninfiltrating
Gene Dosage
prognosis
infiltration
Infiltration
marking
Proteogenomics

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Consortia Oslo Breast Cancer Research Consortium (OSBREAC) (2019). Breast cancer quantitative proteome and proteogenomic landscape. Nature communications, 10(1), [1600]. https://doi.org/10.1038/s41467-019-09018-y

Breast cancer quantitative proteome and proteogenomic landscape. / Consortia Oslo Breast Cancer Research Consortium (OSBREAC).

In: Nature communications, Vol. 10, No. 1, 1600, 01.12.2019.

Research output: Contribution to journalArticle

Consortia Oslo Breast Cancer Research Consortium (OSBREAC) 2019, 'Breast cancer quantitative proteome and proteogenomic landscape', Nature communications, vol. 10, no. 1, 1600. https://doi.org/10.1038/s41467-019-09018-y
Consortia Oslo Breast Cancer Research Consortium (OSBREAC). Breast cancer quantitative proteome and proteogenomic landscape. Nature communications. 2019 Dec 1;10(1). 1600. https://doi.org/10.1038/s41467-019-09018-y
Consortia Oslo Breast Cancer Research Consortium (OSBREAC). / Breast cancer quantitative proteome and proteogenomic landscape. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{57057f7765e44812af40baa40b81160b,
title = "Breast cancer quantitative proteome and proteogenomic landscape",
abstract = "In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.",
author = "{Consortia Oslo Breast Cancer Research Consortium (OSBREAC)} and Johansson, {Henrik J.} and Fabio Socciarelli and Vacanti, {Nathaniel M.} and Haugen, {Mads H.} and Yafeng Zhu and Ioannis Siavelis and Alejandro Fernandez-Woodbridge and Aure, {Miriam R.} and Bengt Sennblad and Mattias Vesterlund and Branca, {Rui M.} and Orre, {Lukas M.} and Mikael Huss and Erik Fredlund and Elsa Beraki and {\O}ystein Garred and Jorrit Boekel and Torill Sauer and Wei Zhao and Silje Nord and H{\"o}glander, {Elen K.} and Jans, {Daniel C.} and Hjalmar Brismar and Haukaas, {Tonje H.} and Bathen, {Tone F.} and Ellen Schlichting and Bj{\o}rn Naume and J{\"u}rgen Geisler and Solveig Hofvind and Olav Engebr{\aa}ten and Geitvik, {Gry Aarum} and Anita Langer{\o}d and Rolf K{\aa}resen and M{\ae}landsmo, {Gunhild Mari} and Therese S{\o}rlie and Skjerven, {Helle Kristine} and Daehoon Park and Hartman-Johnsen, {Olaf Johan} and Torben Luders and Elin Borgen and Kristensen, {Vessela N.} and Russnes, {Hege G.} and Lingj{\ae}rde, {Ole Christian} and Gordon Mills and Sahlberg, {Kristine K.} and B{\o}rresen-Dale, {Anne Lise} and Janne Lehti{\"o}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-09018-y",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Breast cancer quantitative proteome and proteogenomic landscape

AU - Consortia Oslo Breast Cancer Research Consortium (OSBREAC)

AU - Johansson, Henrik J.

AU - Socciarelli, Fabio

AU - Vacanti, Nathaniel M.

AU - Haugen, Mads H.

AU - Zhu, Yafeng

AU - Siavelis, Ioannis

AU - Fernandez-Woodbridge, Alejandro

AU - Aure, Miriam R.

AU - Sennblad, Bengt

AU - Vesterlund, Mattias

AU - Branca, Rui M.

AU - Orre, Lukas M.

AU - Huss, Mikael

AU - Fredlund, Erik

AU - Beraki, Elsa

AU - Garred, Øystein

AU - Boekel, Jorrit

AU - Sauer, Torill

AU - Zhao, Wei

AU - Nord, Silje

AU - Höglander, Elen K.

AU - Jans, Daniel C.

AU - Brismar, Hjalmar

AU - Haukaas, Tonje H.

AU - Bathen, Tone F.

AU - Schlichting, Ellen

AU - Naume, Bjørn

AU - Geisler, Jürgen

AU - Hofvind, Solveig

AU - Engebråten, Olav

AU - Geitvik, Gry Aarum

AU - Langerød, Anita

AU - Kåresen, Rolf

AU - Mælandsmo, Gunhild Mari

AU - Sørlie, Therese

AU - Skjerven, Helle Kristine

AU - Park, Daehoon

AU - Hartman-Johnsen, Olaf Johan

AU - Luders, Torben

AU - Borgen, Elin

AU - Kristensen, Vessela N.

AU - Russnes, Hege G.

AU - Lingjærde, Ole Christian

AU - Mills, Gordon

AU - Sahlberg, Kristine K.

AU - Børresen-Dale, Anne Lise

AU - Lehtiö, Janne

PY - 2019/12/1

Y1 - 2019/12/1

N2 - In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

AB - In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=85064079271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064079271&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-09018-y

DO - 10.1038/s41467-019-09018-y

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1600

ER -